Advanced Adenoma Detection With 3D Imaging Device During Colonoscopy

Launched by XIJING HOSPITAL OF DIGESTIVE DISEASES · Apr 4, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new 3-dimensional (3D) imaging device to see if it can better detect high-risk adenomas (a type of polyp that can develop into cancer) during colonoscopy, a procedure used to look inside the colon. The study aims to understand whether this advanced imaging helps doctors identify these potentially harmful growths more effectively than the traditional 2-dimensional (2D) imaging. Additionally, researchers will monitor participants for any side effects that may occur during the colonoscopy.

To participate in this study, individuals need to be between 18 to 75 years old and scheduled for a diagnostic colonoscopy. They should not have a history of certain conditions like inflammatory bowel disease or previous colorectal cancer. Participants will undergo the colonoscopy using either the 3D or 2D imaging device and will be followed for up to 30 days afterward to check for any complications. This trial is not yet recruiting participants, but it represents an important step in improving colon cancer screening methods.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18-75 years;
• • Patients with indications for colonoscopy and receiving diagnostic colonoscopy, without history of inflammatory bowel disease, colorectal cancer, polypectomy or polyposis syndromes;
• • Signing the written informed consent;
• Exclusion Criteria:
• • Patients with polyposis syndromes (e.g., Peutz-Jeghers syndrome, Cronkhite-Canada syndrome, familial adenomatous polyposis \[FAP\], Lynch syndrome, etc.);
• • Patients with a history of colorectal polypectomy and pathological diagnosed as adenoma;
• • Patients with a history of colorectal adenocarcinoma or alarming symptoms;
• • Patients with a history of inflammatory bowel disease;
• • Patients with mental illness or severe functional disorder who cannot cooperate with colonoscopy;
• • Patients with severe cardiopulmonary insufficiency;
• • Patients with severe coagulation disorders or high bleeding risk (platelets \<50×10⁹/L, INR \>1.5; discontinuation of antithrombotic drugs should follow the 2012 Japanese Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment and the2017 Appendix on Anticoagulants Including Direct Oral Anticoagulants;
• • Patients with severe electrolyte imbalances;
• • Patients with acute peritonitis or suspected intestinal perforation;
• • Patients with toxic megacolon;
• • Patients with stage 3 or higher hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg);
• • Patients with untreated severe abdominal hernia, intestinal obstruction;
• • Patients with intestinal strictures of any cause;
• • Pregnancy and lactation.